Market Access Barriers

In the unforgiving arena of European healthcare economics, innovation alone just isn't enough. Behind every failed MedTech launch lies the same devastating truth, where brilliant technology died not from underestimating the health system, but from underestimating the challenge ahead.

Market access addresses the problem by assessing barriers to uptake and proposing and implementing strategies to overcome these barriers. However, successful reimbursement does not mean that all eligible patients will receive the new treatment, nor will they necessarily have 'access' to it.

_{York Health Economics Consortium}

Barriers tend to bury promising innovations in bureaucratic red tape, evidence gaps, and systemic resistance. While you're perfecting your device, they’re waiting to devour all those years of research and design investment you’ve put in, and in turn, patient hope.

Missing payment codes

Imagine hearing these words. "We love your device, but there's nowhere to bill for it."  While your revolutionary design wins CE marking, receives glowing clinical reviews, and demonstrates clear patient benefits, no payment pathway within NHS tariffs or European DRG systems means just that. No payment.  Without appropriate OPCS-4 classifications, DRG groupings, or fee schedule entries, your breakthrough will become commercially invisible. Trusts won’t be able to justify purchasing decisions. Private insurers won't reimburse. And your innovation will exist in a payment void where clinical excellence means nothing.

Not that these hurdles would let you get that far.

Consider an innovative wound healing device that spent three years in European regulatory approval, only to discover that existing payment codes covered traditional dressings but not advanced bio-engineered alternatives. The result would mean commercial paralysis across major European markets.

Early payment pathway mapping is quite literally about business survival. Before investing millions in clinical trials, identify exactly how your device fits within existing reimbursement frameworks. NHS England's payment pathway processes, for example, German DRG negotiations and even French T2A classifications, each require different evidence packages and timelines. The smart money integrates payment pathway development into clinical strategy, from day one.

Sorry. Your data isn't compelling enough for our assessment committee.

Weak clinical proof

European HTA bodies have become increasingly ruthless in their evidence evaluation. NICE, G-BA, HAS, and other assessment authorities now demand water-tight clinical and economic proof that many innovators simply cannot provide. The harsh truth is, a single study with surrogate endpoints won't survive modern HTA scrutiny. European assessors want randomised controlled trials with patient-relevant outcomes, health economic models meeting their methodological standards, and real-world evidence to demonstrate sustained benefits. Anything less will guarantee rejection.

One promising health management system recently faced unanimous rejection across three European HTA reviews because its evidence package relied heavily on biomarker improvements rather than demonstrable patient outcomes. Use knowledge like this to your advantage.

European-focused evidence generation requires an understanding of each HTA body's specific requirements before study design begins. NICE's methods guides differ significantly from G-BA's evidence standards or HAS assessment frameworks. Generic clinical programmes designed for FDA approval often fail European HTA evaluation completely. Successful companies now employ dedicated European evidence teams who understand the specific requirements of different assessment bodies and design clinical programmes accordingly.

Unjustified cost concerns

European healthcare systems operate under extreme budget pressure, making cost-effectiveness the ultimate gatekeeper for market access. High prices without demonstrated value create immediate barriers that no amount of clinical brilliance can overcome.

Modern HTA assessments include sophisticated budget impact modelling that examines cost-per-QALY ratios, total system costs, implementation expenses, and opportunity costs of alternative investments. Devices priced above any willingness-to-pay thresholds will face automatic rejection regardless of clinical benefits. An innovation with impressive clinical outcomes can still receive negative NICE guidance. The technology might work brilliantly, but if the economics don't add up, then it will be the end of the road for that device.

The value imperative

European pricing strategies must be built on robust health economic foundations from the development phase onwards. Understanding willingness-to-pay thresholds, budget impact limits, and cost-effectiveness expectations enables strategic pricing that maximises access whilst maintaining commercial viability. The most successful European launches now feature health economists as core development team members, ensuring economic considerations influence everything from clinical endpoint selection to manufacturing cost optimisation.

Restrictive coverage policies

Even positive HTA decisions don't guarantee patient access. Narrow commissioning criteria, restrictive clinical guidelines, and limited treatment pathway integration can eliminate entire patient populations from accessing innovations. NICE guidance might approve your device for specific patient subgroups, but local commissioning policies could restrict access even further. For example, Royal College guidelines might not include your technology in their treatment algorithms. Clinical pathway integration might require additional approvals that take years to secure.

Market access requires more than HTA approval and demands clear pathway integration planning. By engaging clinical societies, commissioning bodies, and pathway developers throughout development, this can help ensure your innovation fits seamlessly into existing care delivery models.

Physician resistance

Clinical resistance remains the final barrier that can destroy even the most perfectly reimbursed innovation. Without physician buy-in, workflow integration, and key opinion leader support, devices will simply gather dust in the hospital storage room. Hospital consultants face overwhelming administrative burdens, resource constraints, and change fatigue, so any new technology that disrupts established workflows, requires extensive training, or lacks peer validation will face automatic resistance regardless of clinical benefits.

Physician engagement needs to begin during development (not after launch). Successful European market access requires clinical champions, peer-to-peer education programmes, and implementation support that addresses the real-world constraints facing healthcare professionals.

Common challenges preventing a radical transformation in MedTech are often an unclear value proposition, cultural resistance, and an unadapted regulatory framework. The adoption of an ecosystem model has the potential to boost productivity and improve the provision of care thanks to greater collaboration and data insights.

_{EY Healthcare}

Your blueprint to survival

These five barriers don't operate in isolation, but reinforce each other to create compound threats that will destroy unprepared innovations. By learning how to understand them will transform these obstacles into your competitive intelligence.

Waypoint checklist

Know thy barriers

• Missing codes means no reimbursement pathway without new codes.
• Payers will demand robust clinical and economic proof (not weak evidence)
• High cost concerns that reveal unjustified pricing will block coverage.
• Narrow coverage rules will limit patient access.
• Physician resistance means low adoption without their buy-in.

Need help with market access?

W can help you to develop comprehensive barrier elimination strategies that anticipate, address, and overcome every obstacle between innovation and patient access. Your breakthrough deserves more than clinical excellence. It deserves strategic market access intelligence to ensure it goes to market, gets paid for, and reaches the patients who need it the most.

Contact us CTA?